Tricks of the TradeTrump's Second TermMy EconomyI've Always Wondered ...

Loading...

0:00
0% played
Support the fact-based journalism you rely on with a donation to Marketplace today. Give Now!
Stories Tagged as

Moderna

COVID-19

Moderna will charge around $130 for its COVID vaccine — and Congress isn't too happy

by Kimberly Adams
Mar 22, 2023
But the pharma company promised that individuals won't pay the full amount.
Moderna CEO Stephane Bancel listens to Sen. Bernie Sanders during a committee hearing on the price of COVID vaccines.
Stefani Reynolds/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

What's the right vaccine strategy to fight against COVID variants?

by Lily Jamali
Aug 16, 2022
The U.K. is targeting the BA.1 subvariant of omicron while the U.S. is targeting the more recent BA.4 and BA.5 omicron strains.
The U.S. government is purchasing a Moderna COVID booster that targets both the BA.4 and BA.5 omicron subvariants.
Justin Sullivan/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

Investors pressure Moderna to broaden global access to vaccine

by Lily Jamali
Dec 28, 2021
The company is under scrutiny over vaccine equity. It received considerable U.S. government help in developing its vaccine.
As the omicron variant spreads, some shareholders of Moderna are criticizing the company, arguing its price for the COVID-19 vaccine is too high for low-income countries.
Angela Weiss/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

The upside of the vaccine rollout for the companies making shots

by Andy Uhler
May 3, 2021
The resulting goodwill may prove useful to Pfizer and Moderna.
Karen Andersen, who covers biotech at Morningstar, says the potential sale of booster shots to ward off variants of COVID-19 could be profitable for Pfizer and Moderna.
Matic Zorman/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

Vaccine delivery across the country faces complex supply chain challenges

by Scott Tong
Dec 10, 2020
Within 24 hours of emergency authorization from the Food and Drug Administration, the vaccine maker Pfizer plans to move the product to patients nationwide.
A worker prepares boxes of vaccines before shipment at a French pharmaceutical company world distribution center.
Joel Saget/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

Moderna asking U.S., European regulators to OK vaccine

by Associated Press
Nov 30, 2020
Moderna is just behind Pfizer and its German partner BioNTech in seeking to begin vaccinations in the U.S. in December.
Joel Saget/AFP via Getty Images
Share Now on:
SHARE
COVID-19

AstraZeneca vaccine is third to show promising data in unprecedented hurry-up race

by Scott Tong
Nov 23, 2020
The COVID-19 vaccine is being produced so quickly due to a combination of factors involving the research community, government, industry and the public.
A volunteer receives a COVID-19 vaccination at the Research Centers of America in Hollywood, Florida.
Chandan Khanna/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

For public good, not for profit.

Donate
COVID-19

How might COVID-19 vaccine makers compete in the marketplace?

by Andy Uhler
Nov 17, 2020
At first, COVID-19 vaccines won't be marketed in the usual sense, because the government will be the main buyer.
A volunteer takes part in a COVID-19 vaccination trial this summer in Hollywood, Florida.
Joe Raedle/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE